Tests used in clinical trials of ovarian cancer to determine if tumors lack the ability to repair their DNA — a status termed “homologous recombination deficiency” (HRD), and likely would respond to treatment with PARP inhibitors — yield inconsistent results, a recent study shows. Study findings were presented in the poster “Comparison of genomic instability test scores used for predicting PARP activity in ovarian cancer,” at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific…
You must be logged in to read/download the full post.
The post Study: Tests Used to Predict Response to PARP Inhibitors Yield Inconsistent Result appeared first on BioNewsFeeds.